No associations were observed between TRAIL and any outcome over the full follow-up period, though select associations were observed at 5 years of follow-up (e.g., excluding women with blood drawn within 3 months after breast surgery (breast cancer-specific mortality (HRlog2: 1.93 (1.04–3.56); recurrence-free survival (HRlog2: 1.39 (1.00–1.93), Additional file 1: Table S4). The gene discussed is TNFSF10; the disease is breast carcinoma.